JasminC的个人主页 - 老虎社区

JasminC

JasminC

暂无个人介绍

IP属地：未知

4关注

2粉丝

0主题

0勋章

2021-08-13

加油了!!

BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster

2021-08-12

Thanks for this article..Provide very realistic info

抱歉，原内容已删除

去老虎APP查看更多动态

{"i18n":{"language":"zh_CN"},"userPageInfo":{"id":"3583627365286157","uuid":"3583627365286157","gmtCreate":1620533531422,"gmtModify":1628776906921,"name":"JasminC","pinyin":"jasminc","introduction":"","introductionEn":"","signature":"","avatar":"https://static.tigerbbs.com/7e195c1da5d7eadb557c0c9b61bceed5","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":2,"headSize":4,"tweetSize":2,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"35ec162348d5460f88c959321e554969-3","templateUuid":"35ec162348d5460f88c959321e554969","name":"传说交易员","description":"证券或期货账户累计交易次数达到300次","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2025.01.02","exceedPercentage":"93.02%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"228c86a078844d74991fff2b7ab2428d-1","templateUuid":"228c86a078844d74991fff2b7ab2428d","name":"投资经理虎","description":"证券账户累计交易金额达到10万美元","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.54%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.09.22","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"976c19eed35f4cd78f17501c2e99ef37-1","templateUuid":"976c19eed35f4cd78f17501c2e99ef37","name":"博闻投资者","description":"累计交易超过10只正股","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"post","tweets":[{"id":894419921,"gmtCreate":1628846564963,"gmtModify":1633689036065,"author":{"id":"3583627365286157","authorId":"3583627365286157","name":"JasminC","avatar":"https://static.tigerbbs.com/7e195c1da5d7eadb557c0c9b61bceed5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583627365286157","authorIdStr":"3583627365286157"},"themes":[],"htmlText":"加油了!!","listText":"加油了!!","text":"加油了!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/894419921","repostId":"2158325931","repostType":4,"repost":{"id":"2158325931","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1628776169,"share":"https://www.laohu8.com/m/news/2158325931?lang=&edition=full","pubTime":"2021-08-12 21:49","market":"us","language":"en","title":"BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster","url":"https://stock-news.laohu8.com/highlight/detail?id=2158325931","media":"Tiger Newspress","summary":"BioNTech and Moderna stock rose in early trading on Thursday, on track to recover some of the previo","content":"<p>BioNTech&nbsp;and Moderna&nbsp;stock rose in&nbsp;early&nbsp;trading&nbsp;on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.</p>\n<p><img src=\"https://static.tigerbbs.com/2860e1c0dcbf5f35624516c9d0ff29db\" tg-width=\"895\" tg-height=\"647\" width=\"100%\" height=\"auto\"></p>\n<p>BioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.</p>\n<p>The WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.</p>\n<p>There is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.</p>\n<p>BioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.</p>\n<p>The conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.</p>\n<p>Pfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBioNTech, Moderna Gain on Report of FDA’s Likely Nod for Booster\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-08-12 21:49</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BioNTech&nbsp;and Moderna&nbsp;stock rose in&nbsp;early&nbsp;trading&nbsp;on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.</p>\n<p><img src=\"https://static.tigerbbs.com/2860e1c0dcbf5f35624516c9d0ff29db\" tg-width=\"895\" tg-height=\"647\" width=\"100%\" height=\"auto\"></p>\n<p>BioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.</p>\n<p>The WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.</p>\n<p>There is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.</p>\n<p>BioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.</p>\n<p>The conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.</p>\n<p>Pfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"PFE":"辉瑞","BNTX":"BioNTech SE","MRNA":"Moderna, Inc."},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158325931","content_text":"BioNTech and Moderna stock rose in early trading on Thursday, on track to recover some of the previous session’s losses, following a report in the Wall Street Journal that the FDA could authorize Covid-19 booster shots for immunocompromised people.\n\nBioNTech and Moderna were up 3.96% and 2% after plunging 14% and 15.6% in the previous session, respectively. Pfizer (NYSE:PFE), which shed 4% on Wednesday, was up 1%.\nThe WSJ reported that the Food and Drug Administration is nearing a decision to authorize booster shots for people with weak immunity amid a surge in new COVID cases because of the rapid spread of the delta variant.\nThere is growing evidence that two shots of the vaccines are inadequate for people with low immunity. Vaccine makers plan to approach the FDA this month or next for approval to their booster shots.\nBioNTech, Moderna and Pfizer all closed lower Wednesday following news that Europe’s drug regulator is studying three new conditions reported by a small number of people after getting Covid-19 shots to assess if they may be possible side-effects.\nThe conditions were reported in patients who took the mRNA vaccines made by either Moderna or BioNTech-Pfizer.\nPfizer and BioNTech are collaborating on the research and marketing of their COVID-19 vaccine. Expenses and profit from the vaccine are split equally between Pfizer and BioNTech.","news_type":1},"isVote":1,"tweetType":1,"viewCount":269,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0},{"id":895201448,"gmtCreate":1628743903484,"gmtModify":1633689818982,"author":{"id":"3583627365286157","authorId":"3583627365286157","name":"JasminC","avatar":"https://static.tigerbbs.com/7e195c1da5d7eadb557c0c9b61bceed5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583627365286157","authorIdStr":"3583627365286157"},"themes":[],"htmlText":"Thanks for this article..Provide very realistic info","listText":"Thanks for this article..Provide very realistic info","text":"Thanks for this article..Provide very realistic info","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/895201448","repostId":"2158936289","repostType":4,"isVote":1,"tweetType":1,"viewCount":359,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"hots":[{"id":895201448,"gmtCreate":1628743903484,"gmtModify":1633689818982,"author":{"id":"3583627365286157","authorId":"3583627365286157","name":"JasminC","avatar":"https://static.tigerbbs.com/7e195c1da5d7eadb557c0c9b61bceed5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583627365286157","authorIdStr":"3583627365286157"},"themes":[],"htmlText":"Thanks for this article..Provide very realistic info","listText":"Thanks for this article..Provide very realistic info","text":"Thanks for this article..Provide very realistic info","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/895201448","repostId":"2158936289","repostType":4,"repost":{"id":"2158936289","kind":"highlight","pubTimestamp":1628734800,"share":"https://www.laohu8.com/m/news/2158936289?lang=&edition=full","pubTime":"2021-08-12 10:20","market":"us","language":"en","title":"3 Unstoppable Investments Everyone Needs in Their Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2158936289","media":"Motley Fool","summary":"These investments can help boost your savings and build long-term wealth.","content":"<p>Building a strong investment portfolio can be challenging, because there are seemingly limitless options to choose from. If you're new to the stock market, all of those choices can be overwhelming.</p>\n<p>The good news is that it's easier than you may think to create a solid core portfolio. These three types of investments are a fantastic choice regardless of where you are on your investing journey, and they can help send your savings to the moon.</p>\n<p><img src=\"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F638446%2Fperson-holding-hundred-dollar-bills-copy-2.jpg&amp;w=700&amp;op=resize\" tg-width=\"700\" tg-height=\"415\" referrerpolicy=\"no-referrer\" width=\"100%\" height=\"auto\"></p>\n<p>Image source: Getty Images.</p>\n<h2>1. S&amp;P 500 ETFs</h2>\n<p>An <b>S&amp;P 500</b> ETF is a group of stocks that is designed to mirror the performance of the S&amp;P 500 index itself. That means each of these funds contains around 500 stocks from the largest U.S.-based companies.</p>\n<p>This type of investment is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of the more stable and lower-risk options. While the S&amp;P 500 does experience short-term volatility, it's earned an average rate of return of around 10% per year since its inception. In other words, the highs and lows each year average out to around 10% annually over time.</p>\n<p>These funds are also very likely to recover from market crashes. The S&amp;P 500 has endured countless corrections and crashes over the years, but it's survived each and every one so far. Although there are never any guarantees in investing, there's a very good chance it will recover from any future crashes as well.</p>\n<p><b>Where to get started:</b> There are many S&amp;P 500 ETFs to choose from, and they're all similar. Some of the best options include:</p>\n<ul>\n <li><b><a href=\"https://laohu8.com/S/VOO\">Vanguard S&amp;P 500 ETF</a> </b></li>\n <li><b><a href=\"https://laohu8.com/S/IVV\">iShares Core S&amp;P 500 ETF</a> </b></li>\n <li><b><a href=\"https://laohu8.com/S/SPY\">S&amp;P500 ETF</a> </b></li>\n</ul>\n<h2>2. Growth ETFs</h2>\n<p>A growth ETF is a fund that contains stocks with higher-than-average growth rates. The advantage of this type of investment is that you may earn higher returns than you would with a broad-market fund like an S&amp;P 500 ETF.</p>\n<p>The downside, though, is that growth ETFs can be on the riskier side. High-growth stocks can be more volatile than their more established counterparts, so you may see more ups and downs with this type of fund than you would with an S&amp;P 500 ETF.</p>\n<p>That said, many growth ETFs include companies that have experienced phenomenal growth but are also strong businesses, such as <a href=\"https://laohu8.com/S/AMZN\">Amazon.com</a>, <a href=\"https://laohu8.com/S/AAPL\">Apple</a>, and <a href=\"https://laohu8.com/S/MSFT\">Microsoft</a>. These organizations are still subject to volatility in the short term, but it's very likely they'll experience long-term growth.</p>\n<p><b>Where to get started:</b> It's important to choose carefully when investing in a growth ETF, because not all funds are created equal. Some funds only contain smaller organizations from niche industries, for example, which poses more risk than a fund that includes large corporations from a variety of industries. A few of the stronger growth ETFs include:</p>\n<ul>\n <li><b><a href=\"https://laohu8.com/S/VUG\">Vanguard Growth Index Fund ETF Shares</a> </b></li>\n <li><b><a href=\"https://laohu8.com/S/IWO\">iShares Russell 2000 Growth ETF</a> </b></li>\n <li><b><a href=\"https://laohu8.com/S/QQQ\">NASDAQ-100 Index ETF</a> </b></li>\n</ul>\n<h2>3. Dividend ETFs</h2>\n<p>A dividend ETF is a collection of stocks that will actually pay you to own them. Some companies pay a portion of their profits back to shareholders each quarter or year, which is called a dividend. By investing in a dividend ETF, you'll earn quarterly or annual dividend payments in addition to the fund's normal earnings.</p>\n<p>By investing consistently over time, you could build a source of passive income with dividend ETFs. Most funds also offer the opportunity to reinvest your dividends and buy more shares of that particular ETF. By reinvesting, you can gradually buy more shares without having to pay more money out of pocket. And the more shares you own, the more you'll receive in dividends.</p>\n<p><b>Where to get started:</b> As with growth ETFs, all dividend ETFs are different and offer varying levels of risk and reward. Some of the most popular funds include:</p>\n<ul>\n <li><b><a href=\"https://laohu8.com/S/VIG\">Vanguard Dividend Appreciation Index Fund ETF Shares</a> </b></li>\n <li><b><a href=\"https://laohu8.com/S/HDV\">iShares Core High Dividend ETF</a> </b></li>\n <li><b><a href=\"https://laohu8.com/S/SCHD\">Schwab US Dividend Equity ETF</a> </b></li>\n</ul>\n<p>Choosing the right investments isn't as challenging as it may seem. By building a portfolio filled with solid funds, you'll be on your way to generating long-term wealth.</p>","source":"fool_stock","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>3 Unstoppable Investments Everyone Needs in Their Portfolio</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n3 Unstoppable Investments Everyone Needs in Their Portfolio\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-08-12 10:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/08/11/3-unstoppable-investments-everyone-needs-in-their/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Building a strong investment portfolio can be challenging, because there are seemingly limitless options to choose from. If you're new to the stock market, all of those choices can be overwhelming.\n...</p>\n\n<a href=\"https://www.fool.com/investing/2021/08/11/3-unstoppable-investments-everyone-needs-in-their/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://www.fool.com/investing/2021/08/11/3-unstoppable-investments-everyone-needs-in-their/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2158936289","content_text":"Building a strong investment portfolio can be challenging, because there are seemingly limitless options to choose from. If you're new to the stock market, all of those choices can be overwhelming.\nThe good news is that it's easier than you may think to create a solid core portfolio. These three types of investments are a fantastic choice regardless of where you are on your investing journey, and they can help send your savings to the moon.\n\nImage source: Getty Images.\n1. S&P 500 ETFs\nAn S&P 500 ETF is a group of stocks that is designed to mirror the performance of the S&P 500 index itself. That means each of these funds contains around 500 stocks from the largest U.S.-based companies.\nThis type of investment is one of the more stable and lower-risk options. While the S&P 500 does experience short-term volatility, it's earned an average rate of return of around 10% per year since its inception. In other words, the highs and lows each year average out to around 10% annually over time.\nThese funds are also very likely to recover from market crashes. The S&P 500 has endured countless corrections and crashes over the years, but it's survived each and every one so far. Although there are never any guarantees in investing, there's a very good chance it will recover from any future crashes as well.\nWhere to get started: There are many S&P 500 ETFs to choose from, and they're all similar. Some of the best options include:\n\nVanguard S&P 500 ETF \niShares Core S&P 500 ETF \nS&P500 ETF \n\n2. Growth ETFs\nA growth ETF is a fund that contains stocks with higher-than-average growth rates. The advantage of this type of investment is that you may earn higher returns than you would with a broad-market fund like an S&P 500 ETF.\nThe downside, though, is that growth ETFs can be on the riskier side. High-growth stocks can be more volatile than their more established counterparts, so you may see more ups and downs with this type of fund than you would with an S&P 500 ETF.\nThat said, many growth ETFs include companies that have experienced phenomenal growth but are also strong businesses, such as Amazon.com, Apple, and Microsoft. These organizations are still subject to volatility in the short term, but it's very likely they'll experience long-term growth.\nWhere to get started: It's important to choose carefully when investing in a growth ETF, because not all funds are created equal. Some funds only contain smaller organizations from niche industries, for example, which poses more risk than a fund that includes large corporations from a variety of industries. A few of the stronger growth ETFs include:\n\nVanguard Growth Index Fund ETF Shares \niShares Russell 2000 Growth ETF \nNASDAQ-100 Index ETF \n\n3. Dividend ETFs\nA dividend ETF is a collection of stocks that will actually pay you to own them. Some companies pay a portion of their profits back to shareholders each quarter or year, which is called a dividend. By investing in a dividend ETF, you'll earn quarterly or annual dividend payments in addition to the fund's normal earnings.\nBy investing consistently over time, you could build a source of passive income with dividend ETFs. Most funds also offer the opportunity to reinvest your dividends and buy more shares of that particular ETF. By reinvesting, you can gradually buy more shares without having to pay more money out of pocket. And the more shares you own, the more you'll receive in dividends.\nWhere to get started: As with growth ETFs, all dividend ETFs are different and offer varying levels of risk and reward. Some of the most popular funds include:\n\nVanguard Dividend Appreciation Index Fund ETF Shares \niShares Core High Dividend ETF \nSchwab US Dividend Equity ETF \n\nChoosing the right investments isn't as challenging as it may seem. By building a portfolio filled with solid funds, you'll be on your way to generating long-term wealth.","news_type":1},"isVote":1,"tweetType":1,"viewCount":359,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":894419921,"gmtCreate":1628846564963,"gmtModify":1633689036065,"author":{"id":"3583627365286157","authorId":"3583627365286157","name":"JasminC","avatar":"https://static.tigerbbs.com/7e195c1da5d7eadb557c0c9b61bceed5","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3583627365286157","authorIdStr":"3583627365286157"},"themes":[],"htmlText":"加油了!!","listText":"加油了!!","text":"加油了!!","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/894419921","repostId":"2158325931","repostType":4,"isVote":1,"tweetType":1,"viewCount":269,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"CN","totalScore":0}],"lives":[]}